SunVault Energy, Inc., a prominent supplier of cost effective generation and energy storage to the solar industry, announced today that it has submitted an application to ATCO Electric to interconnect its proposed generation unit to ATCO Electric’s distribution systems. SunVault anticipates the construction of a 500 kW solar electric generation unit with potential growth to 1 MW within a 12-month period. Daystar Technologies, Inc. has been chosen to build the unit, but SunVault will serve as the sole operator and owner of the unit.
Based on current market figures, the Company expects the unit to generate $115.00 of revenue per hour for the hours that the unit is actively supplying electrical energy to the power distribution grid, resulting in approximately $167,000 per year. The potential expansion to 1 MW would double expected revenues to approximately $230 per hour during the hours of energy supply to the grid based on average current market prices. If the unit capacity is boosted to 1 MW, the unit will have fully active energy storage.
“We continue to be optimistic that we will be able to generate stable revenue from this type of unit in the Alberta, Canada market and by participating in the Alberta energy system through interconnection to the grid for the sale of power. We plan to use this unit as way to test and develop our PolyCell™ and All-in-One™ technology platforms. This unit will also provide us with real-world access, data and a key-learning opportunity at the system/architectural level,” commented SunVault President and CEO John Crawford.
SunVault will continue its pursuit of additional opportunities as it fits into the Company mandate and growth plans. Producing on-going revenues while enabling the ability to develop and utilize the Company’s PolyCell™ energy storage, All-in-One™ and Vertical Solar Appliance technology platforms within a real world operating environment is anticipated to accelerate development and enhance existing and future renewable project installations.
For further information, please visit www.sunvaultenergy.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Friday, October 25, 2013
ARRAYit Corp. (ARYC) Receives Purchase Order from University of California for Life Science Products
ARRAYit, a life science technology company engaged in the development, manufacture and marketing of life science tools and integrated systems, has received from the University of California a $104,000 purchase order for the company’s life science instruments product line.
The University of California is one of the nation’s most prestigious educational and research systems comprising 442,000 students and employees scattered across 10 campuses, and has an investment portfolio of retirement, endowment and cash assets of $78.5 billion.
ARYC said it will book the recent sale to the University of California as revenue and earnings in the current quarter.
In addition to being installed at the University of California, ARYC’s microarray platform is currently installed in 4,000 research centers globally, as well as in numerous leading academic, government, biotech, pharmaceutical and diagnostic companies.
By providing analysis of genetic variation, biological function and diagnostics with inherent versatility, affordability and performance, ARYC is favored among researchers and empowers researchers to manufacture, scan and analyze microarrays prepared from cellular and synthetic DNA, RNA, proteins, peptides, carbohydrates, lipids, small molecules, tissues, whole cells and nanoparticles.
For more information visit www.arrayit.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The University of California is one of the nation’s most prestigious educational and research systems comprising 442,000 students and employees scattered across 10 campuses, and has an investment portfolio of retirement, endowment and cash assets of $78.5 billion.
ARYC said it will book the recent sale to the University of California as revenue and earnings in the current quarter.
In addition to being installed at the University of California, ARYC’s microarray platform is currently installed in 4,000 research centers globally, as well as in numerous leading academic, government, biotech, pharmaceutical and diagnostic companies.
By providing analysis of genetic variation, biological function and diagnostics with inherent versatility, affordability and performance, ARYC is favored among researchers and empowers researchers to manufacture, scan and analyze microarrays prepared from cellular and synthetic DNA, RNA, proteins, peptides, carbohydrates, lipids, small molecules, tissues, whole cells and nanoparticles.
For more information visit www.arrayit.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Boston Therapeutics, Inc. (BTHE) and America’s Sugar Monster
The formal description for Boston Therapeutics is of a pharmaceutical company focused on the development of novel compounds based on complex carbohydrate chemistry to address unmet medical needs in diabetes. But the company’s potential, as an investment and in terms of its possible effect on the tens of millions of people with Type 2 diabetes, is far more dramatic. CEO David Platt is blunt about it, saying in a recent interview with the New Hampshire Union Leader “We believe that what we have in our hands is an absolute blockbuster”.
The blockbuster in question is the company’s one-of-a-kind proprietary polysaccharide, PAZ320, that represents a totally new way of treating type 2 diabetes, currently afflicting over 25 million people in the U.S. alone. PAZ320 is a chewable, locally acting complex carbohydrate-based compound that works in the gastrointestinal tract to directly block the enzymes that digest sugar. The demonstrated result is a dramatic reduction in the amount of glucose in the blood stream from carbohydrate rich meals. A phase II study of PAZ320 showed a 40 percent reduction of post-meal glucose in the blood of 45 percent of patients treated with PAZ320. There’s never been anything like it.
In spite of the enormous possibilities for Boston Therapeutics, CEO David Platt seems even more enthused about the development’s potential benefit for public health. With obesity becoming the country’s number one health issue, and even young people being faced with type 2 diabetes at levels never before experienced, Platt has an almost missionary zeal for taming the nation’s sugar monster. In the same newspaper interview, he emphasized the deadly and critical nature of the challenge, saying “It’s very simple. Sugar kills. End of story”.
For additional information, visit the company’s website at www.BostonTI.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The blockbuster in question is the company’s one-of-a-kind proprietary polysaccharide, PAZ320, that represents a totally new way of treating type 2 diabetes, currently afflicting over 25 million people in the U.S. alone. PAZ320 is a chewable, locally acting complex carbohydrate-based compound that works in the gastrointestinal tract to directly block the enzymes that digest sugar. The demonstrated result is a dramatic reduction in the amount of glucose in the blood stream from carbohydrate rich meals. A phase II study of PAZ320 showed a 40 percent reduction of post-meal glucose in the blood of 45 percent of patients treated with PAZ320. There’s never been anything like it.
In spite of the enormous possibilities for Boston Therapeutics, CEO David Platt seems even more enthused about the development’s potential benefit for public health. With obesity becoming the country’s number one health issue, and even young people being faced with type 2 diabetes at levels never before experienced, Platt has an almost missionary zeal for taming the nation’s sugar monster. In the same newspaper interview, he emphasized the deadly and critical nature of the challenge, saying “It’s very simple. Sugar kills. End of story”.
For additional information, visit the company’s website at www.BostonTI.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
MMRGlobal, Inc. (MMRF) Video Chart for Friday, October 25, 2013
The MMRF chart is sitting on a strong support level at 2.5 cents. The indicators are showing signs of a swing towards bullishness as the 50 day moving average converges with the pps, putting the chart in a position to try and make a strong move.
To view the video chart, visit the following link: http://www.qualitystocks.net/videocharts
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
To view the video chart, visit the following link: http://www.qualitystocks.net/videocharts
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Cardium Therapeutics, Inc.’s (CXM) Generx® Addresses Global Cardiac Threat with Revolutionary Potential
Cardium Therapeutics has developed a unique portfolio of businesses and product opportunities in the fields of health sciences and regenerative medicine. Among other opportunities in its portfolio, the company’s lead clinical development product candidate, Generx®, is being developed to treat patients with advanced coronary artery disease (CAD). The market for this disease is tremendous – in 2012, CAD was the most common cause of death in the world, according to the World Health Organization.
While healthy lifestyle changes greatly reduce the risk and prominence of CAD, it remains a significant medical challenge worldwide and is especially an issue in markets where persons with the disease may not have access to healthy lifestyle education or adequate healthcare.
Cardium’s focus is on providing Generx to individuals in international markets outside the United States. The therapeutic candidate is designed as an alternative for patients who may not be candidates for or who don’t have access to the costly and invasive surgical procedures such as coronary artery bypass surgery and angioplasty/stents. In the U.S., these procedures can cost a staggering $50,000-$100,000 over a five-year period following the initial treatment.
Generx is a regenerative medicine therapy that stimulates structural and physiological changes in the heart by promoting the growth of new collateral blood vessels following a significantly less invasive, one-time injection into the heart via standard cardiac infusion catheter. The candidate’s capability to elicit blood vessel growth greatly contrasts with traditional drug therapies that provide relief for anginal chest pain without changing the underlying disease.
Cardium is conducting ASPIRE Phase 3 registration at leading cardiology centers in the Russian Federation to evaluate the therapeutic effects of Generx in patients with myocardial ischemia due to coronary artery disease.
For more information visit www.cardiumthx.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
While healthy lifestyle changes greatly reduce the risk and prominence of CAD, it remains a significant medical challenge worldwide and is especially an issue in markets where persons with the disease may not have access to healthy lifestyle education or adequate healthcare.
Cardium’s focus is on providing Generx to individuals in international markets outside the United States. The therapeutic candidate is designed as an alternative for patients who may not be candidates for or who don’t have access to the costly and invasive surgical procedures such as coronary artery bypass surgery and angioplasty/stents. In the U.S., these procedures can cost a staggering $50,000-$100,000 over a five-year period following the initial treatment.
Generx is a regenerative medicine therapy that stimulates structural and physiological changes in the heart by promoting the growth of new collateral blood vessels following a significantly less invasive, one-time injection into the heart via standard cardiac infusion catheter. The candidate’s capability to elicit blood vessel growth greatly contrasts with traditional drug therapies that provide relief for anginal chest pain without changing the underlying disease.
Cardium is conducting ASPIRE Phase 3 registration at leading cardiology centers in the Russian Federation to evaluate the therapeutic effects of Generx in patients with myocardial ischemia due to coronary artery disease.
For more information visit www.cardiumthx.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
CytRx Corp. (CYTR) Continues to Build Oncology Portfolio, Headed by Lead Candidate Aldoxorubicin
CytRx is a biopharmaceutical research and development company with a particular focus on expanding its pipeline of oncology candidates in various stages of preclinical and clinical development.
Aldoxorubicin is the company’s novel version of the commonly prescribed chemotherapeutic agent doxorubicin, which is a standard chemotherapeutic treatment for a variety of cancers and is used either alone or in combination with other chemotherapy agents. Aldoxorubicin differs in that it has the potential to safely deliver greater amounts of doxorubicin directly to the tumor compared with standard doxorubicin treatment, which the company believes could lead to improved efficacy.
CytRx holds the exclusive worldwide rights to aldoxorubicin. The candidate has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with soft tissue sarcomas and pancreatic cancer.
CytRx recently announced favorable results from its phase 1b/2 clinical trial with aldoxorubicin in patients with advanced solid tumors, and has initiated a phase 2b international clinical trial in patients with soft tissue sarcomas, and a phase 2 clinical trial in patients with pancreatic cancer.
The company in December plans to report top-line phase 2b data, which the company anticipates will provide the first direct clinical trial comparison of aldoxorubicin with native doxorubicin as a first-line treatment for soft tissue sarcoma.
CytRx also has rights to two additional drug candidates: tamibarotene, for which the company has completed evaluation in the ENABLE Phase 2 clinical trial in lymphocytic leukemia and for which it plans to seek a partnership for further development; and befetinib, which the company is evaluating for further development.
For more information visit www.cytrx.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Aldoxorubicin is the company’s novel version of the commonly prescribed chemotherapeutic agent doxorubicin, which is a standard chemotherapeutic treatment for a variety of cancers and is used either alone or in combination with other chemotherapy agents. Aldoxorubicin differs in that it has the potential to safely deliver greater amounts of doxorubicin directly to the tumor compared with standard doxorubicin treatment, which the company believes could lead to improved efficacy.
CytRx holds the exclusive worldwide rights to aldoxorubicin. The candidate has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with soft tissue sarcomas and pancreatic cancer.
CytRx recently announced favorable results from its phase 1b/2 clinical trial with aldoxorubicin in patients with advanced solid tumors, and has initiated a phase 2b international clinical trial in patients with soft tissue sarcomas, and a phase 2 clinical trial in patients with pancreatic cancer.
The company in December plans to report top-line phase 2b data, which the company anticipates will provide the first direct clinical trial comparison of aldoxorubicin with native doxorubicin as a first-line treatment for soft tissue sarcoma.
CytRx also has rights to two additional drug candidates: tamibarotene, for which the company has completed evaluation in the ENABLE Phase 2 clinical trial in lymphocytic leukemia and for which it plans to seek a partnership for further development; and befetinib, which the company is evaluating for further development.
For more information visit www.cytrx.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Green Automotive Company (GACR) Names Two New Board Members
Green Automotive Company announced earlier today the recruitment of two business leaders, Peter C. Leeds and Carter Read to its Board of Directors.
“We are extremely pleased to add these incredible talents to our company’s board,” stated CEO of Green Automotive Company, Ian Hobday. “Throughout each of their successful careers, both Peter and Carter have demonstrated the highest levels of leadership, vision and sound judgment.”
A well-known businessman, Peter C. Leeds solidified his reputation as a successful promoter and manager of music icons such as Blondie, Roberta Flack, and Les McCann. Following his impressive music industry career, Leeds erected a video production company that subsequently produced The Better Homes and Gardens Idea Notebook for USA Network. In addition he developed a number of financial structures and business arrangements for a number of prominent clients. These have included KULFF Medical and Dr. Robert Jarvic, creator of the Jarvic artificial heart, among many others. Additionally, Peter has served on the board and acted as Vice President for both the Caedmon School and The Juvenile Diabetes Foundation. A major shareholder in GAC, Leeds is an enthusiastic supporter of the automotive industry moving towards zero emission solutions.
With more than three decades of experience in the bus and limousine manufacturing business, Carter Read currently serves as president of Newport Coachworks, a subsidiary of Green Automotive Company. Regarded as an industry trailblazer committed to setting strong standards of product quality, Carter previously led Tiffany Coachworks as its president for 23 years. During his tenure the vehicles were strongly praised for not just their style but reliability and value.
A direct result of Carter’s efforts, Newport Coachworks is currently seen as one of the most innovative bus manufacturing companies in the United States. In a record time of six months, Carter and his team completed tooling for four models of shuttle buses. The company began production by increasing the performance of existing manufacturing technology, delivering products of superior quality designed to fulfill all customer needs. Fully committed to the reduction of pollution and promotion of “green” technologies, Carter and his team are impressively building the first electric shuttle bus to be debuted in 2014.
To learn more please visit, www.thegreenautomotivecompany.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
“We are extremely pleased to add these incredible talents to our company’s board,” stated CEO of Green Automotive Company, Ian Hobday. “Throughout each of their successful careers, both Peter and Carter have demonstrated the highest levels of leadership, vision and sound judgment.”
A well-known businessman, Peter C. Leeds solidified his reputation as a successful promoter and manager of music icons such as Blondie, Roberta Flack, and Les McCann. Following his impressive music industry career, Leeds erected a video production company that subsequently produced The Better Homes and Gardens Idea Notebook for USA Network. In addition he developed a number of financial structures and business arrangements for a number of prominent clients. These have included KULFF Medical and Dr. Robert Jarvic, creator of the Jarvic artificial heart, among many others. Additionally, Peter has served on the board and acted as Vice President for both the Caedmon School and The Juvenile Diabetes Foundation. A major shareholder in GAC, Leeds is an enthusiastic supporter of the automotive industry moving towards zero emission solutions.
With more than three decades of experience in the bus and limousine manufacturing business, Carter Read currently serves as president of Newport Coachworks, a subsidiary of Green Automotive Company. Regarded as an industry trailblazer committed to setting strong standards of product quality, Carter previously led Tiffany Coachworks as its president for 23 years. During his tenure the vehicles were strongly praised for not just their style but reliability and value.
A direct result of Carter’s efforts, Newport Coachworks is currently seen as one of the most innovative bus manufacturing companies in the United States. In a record time of six months, Carter and his team completed tooling for four models of shuttle buses. The company began production by increasing the performance of existing manufacturing technology, delivering products of superior quality designed to fulfill all customer needs. Fully committed to the reduction of pollution and promotion of “green” technologies, Carter and his team are impressively building the first electric shuttle bus to be debuted in 2014.
To learn more please visit, www.thegreenautomotivecompany.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Posts (Atom)
